Published in Medical Letter on the CDC and FDA, July 7th, 2002
The manufacturer of the drug, GlaxoSmithKline, will be implementing a risk management program including a prescribing program to enroll physicians who wish to prescribe Lotronex. The drug's indication has been narrowed to be only for treatment of women with severe, diarrhea-predominant irritable bowel syndrome (IBS) who have failed to respond to conventional IBS therapy. Limiting the use of Lotronex to this severely affected population is intended to maximize the benefit-to-risk...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.